Inhibition of PD-1 Protein by the CRISPR-Cas9 Method as Antitumor Therapy of Non-Small Cell Lung Cancers

Revista da Faculdade de Ciências Médicas de Sorocaba
doi 10.23925/1984-4840.2019v21i1a2
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Portal de Revistas PUC SP

Related search

PD-1 and PD-L1 Expression in Molecularly Selected Non-Small-Cell Lung Cancer Patients

British Journal of Cancer
Cancer ResearchOncology
2014English

Diverse Mechanisms of CRISPR-Cas9 Inhibition by Type IIC Anti-Crispr Proteins

Molecular Cell
Cell BiologyMolecular Biology
2019English

P3.09-05 Significance of the Expression of PD-L1/PD-1 by Tumoral and Immune Cells in Non-Small Cell Lung Cancer.

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P013 Anti-Pd-1 Combination Therapy as Second Line Treatment or Beyond in Patients With Advanced Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Mechanisms of P16INK4A Inactivation in Non Small-Cell Lung Cancers

Oncogene
Cancer ResearchGeneticsMolecular Biology
1998English

Inhibition of Long Non-Coding RNA UCA1 by CRISPR/Cas9 Attenuated Malignant Phenotypes of Bladder Cancer

Oncotarget
Oncology
2016English

Real-World Evidenceand Clinical Observations of the Treatment of Advanced Non-Small Cell Lung Cancer With PD-1/PD-L1 Inhibitors

Scientific Reports
Multidisciplinary
2019English

Hot Spot Mutations in Finnish Non-Small Cell Lung Cancers

Lung Cancer
Cancer ResearchOncologyRespiratory MedicinePulmonary
2016English

Feasibility of Continuing Crizotinib Therapy After RECIST-PD in Advanced Non-Small Cell Lung Cancer Patients With ALK/ROS-1 Mutations

Journal of Cancer
Oncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy